Advertisement
Screener

IGC PHARMA, INC. (IGC) Adjustments to Additional Paid in Capital, Other

2.8 / 5 stars · 68/120 Roast Me

IGC PHARMA, INC. Adjustments to Additional Paid in Capital, Other

IGC PHARMA, INC. (IGC) reported Adjustments to Additional Paid in Capital, Other of $1.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital

us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2026-08-14

  • IGC PHARMA, INC. adjustments to additional paid in capital, other for the quarter ending 2026-06-30 was $1.15M, a 8776.92% increase year-over-year.
  • IGC PHARMA, INC. adjustments to additional paid in capital, other for the quarter ending 2026-03-31 was -$264.00K.
  • IGC PHARMA, INC. adjustments to additional paid in capital, other for the quarter ending 2025-06-30 was $13.00K.
  • IGC PHARMA, INC. adjustments to additional paid in capital, other for the quarter ending 2025-03-31 was $0.00.
  • IGC PHARMA, INC. adjustments to additional paid in capital, other for fiscal 2025 was $200.00K.
  • IGC PHARMA, INC. adjustments to additional paid in capital, other for fiscal 2024 was $0.00.
Period endAdjustments to Additional Paid in Capital, Other 3 monthAdjustments to Additional Paid in Capital, Other 6 monthAdjustments to Additional Paid in Capital, Other 9 monthAdjustments to Additional Paid in Capital, Other 12 monthAdjustments to Additional Paid in Capital, Other 12 month as first filed
2026-06-30$1.15M
10-Q · filed 2026-08-14
$890.00K
10-Q · filed 2026-08-14
2026-03-31-$264.00K
10-Q · filed 2026-05-15
2025-12-31$234.00K
10-KT · filed 2026-03-18
2025-06-30$13.00K
10-Q · filed 2026-08-14
$13.00K
10-Q · filed 2026-08-14
$13.00K
derived: sum of 3 quarters · filed 2026-08-14
$440.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$0.00
10-Q · filed 2026-05-15
$0.00
derived: sum of 2 quarters · filed 2026-05-15
$427.00K
derived: sum of 3 quarters · filed 2026-05-15
$200.00K
10-KT · filed 2026-03-18
2024-12-31$0.00
10-Q · filed 2025-02-14
$427.00K
derived: sum of 2 quarters · filed 2025-11-14
$200.00K
10-Q · filed 2025-02-14
$427.00K
derived: sum of 4 quarters · filed 2025-11-14
2024-09-30$427.00K
10-Q · filed 2025-11-14
$427.00K
10-Q · filed 2025-11-14
$427.00K
derived: sum of 3 quarters · filed 2025-11-14
$427.00K
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30$0.00
10-Q · filed 2025-08-14
$0.00
derived: sum of 2 quarters · filed 2025-08-14
$0.00
derived: sum of 3 quarters · filed 2025-08-14
$0.00
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-27
$0.00
derived: sum of 2 quarters · filed 2025-06-27
$0.00
derived: sum of 3 quarters · filed 2025-06-27
$0.00
10-K · filed 2025-06-27
$500.00K
10-K · filed 2024-06-24
2023-12-31$0.00
10-Q · filed 2025-02-14
$0.00
derived: sum of 2 quarters · filed 2025-02-14
$0.00
10-Q · filed 2025-02-14
2023-09-30$0.00
10-Q · filed 2024-11-12
$0.00
10-Q · filed 2024-11-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
NextCure, Inc. (NXTC)United States$0.024B-0.15